“The U.S. system for pricing drug innovation is forged on a careful balance between innovation and access. On the whole, American consumers consent to market-based pricing for novel drugs as a way to drive investment and reward scientific success. But no system is optimal. Too many patients struggle to obtain access to the resulting breakthroughs. Healthcare costs are straining public and private budgets.
We’ve maintained a fragile political consensus that has long accepted that our market-based model is a suitable compromise for steering capital to the highest reward and also highest-risk endeavors. That political balance is becoming more frayed, at the very moment when the results of these endeavors — measured by new advances — are enormous. We’ve entered an age of unmatched medical breakthroughs, where the opportunity to cure once intractable and deadly diseases is firmly at hand. But our market-based approach needs to be modernized to work better for more consumers and sustain the fragile compact that supports it.
These market-based rewards for innovation are balanced against an expectation that there will be vigorous competition from low cost, generic drugs once patents and other exclusivities have lapsed on the branded medicines. That careful compromise mostly worked for many years. But this implicit bargain faces new strains that are contributing to the growing angst over the rising cost of novel drugs.”
Click here to see more
Relevant and recent posts
Erika Ayers Badan: You Are The Problem (And The Solution)
This is an episode for people grappling with how to manage and how to embrace AI. Good managers in the future will seamlessly balance being…
Thought Leader: Erika Ayers Badan
Patrick McGee: Tesla’s Robotaxi Bait and Switch
Elon Musk called self-driving cars a ‘solved problem’ 10 years ago. So how come he’s still working on it? In a new column, Patrick McGee…
Thought Leader: Patrick McGee
Mike Pence on U.S. Leadership and Global Strategy
Former Vice President of the United States, Mike Pence, shares his thoughts about President Trump’s framework on trying to acquire Greenland, and discusses what he…
Thought Leader: Mike Pence
More with this speaker
Dr. Scott Gottlieb on Finding Cures for Rare Diseases
Thought Leader: Scott Gottlieb
Dr. Scott Gottlieb: What’s Next for Childhood Vaccines
Thought Leader: Scott Gottlieb
Scott Gottlieb on China’s biotech strategy
Thought Leader: Scott Gottlieb